News

BenevolentAI Announces Board Changes

Public disclosure of inside information in accordance with article 17(1) of the Regulation (EU) No 596/2014 on market abuse (Market Abuse Regulation)

London, UK, 25 May 2022: BenevolentAI (“BenevolentAI” or the "Company") (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, today announces the appointment of Dr. Susan Liautaud as a member of the board of directors of the Company (the “Board”) with effect from 30 June 2022. Dr. Susan Liautaud will act as Independent Non-Executive Director of the Company. 

Dr. Susan Liautaud is an experienced board director with extensive and innovative ethics experience. Susan advises global leaders and international corporations in developing strategic solutions to complex ethical and organisational challenges. She holds a PhD in Social Policy from the London School of Economics and Political Science (LSE), a JD from Columbia University Law School, two BAs and a MA from Stanford University, and a MA from the University of London SOAS. She is the author of the new book The Power of Ethics and teaches cutting-edge ethics courses at Stanford University. ​Susan serves on a number of boards and advisory boards, including as Chair of the Council of LSE, as member of the Stanford Institute for Human-Centered Artificial Intelligence Advisory Council, and as Vice Chair of the Global Partnership for Education. Susan’s committee memberships will be determined and announced in due course.

Dr. François Nader, Chairman of BenevolentAI, said: “Susan’s broad global ethics and governance experience makes her a valuable addition to our Board. I am pleased to welcome her to the team and I look forward to working with her on our mission to deliver life-changing medicines to patients and specifically as we look to strengthen our position within the AI-driven drug discovery sector.

Dr. Susan Liautaud, said: “BenevolentAI is unique in how it unites AI with human intelligence and to discover new and more effective medicines, framing the use of AI around ethics principles to secure the best outcomes for patients. I look forward to working closely with the Board as BenevolentAI continues to establish its leadership position in this dynamic sector.”

The Company also announces that Kenneth Mulvany, Founder and Non-Executive Director, and Michael Brennan Co-Founder and Non-Executive Director, will be stepping down from the Board with effect from 30 June 2022 and 30 September 2022, respectively. The Company’s Nomination Committee has initiated steps to seek an additional Non-Executive Director, with any appointment to be announced in due course.

Joanna Shields, Chief Executive Officer of BenevolentAI, said: “On behalf of the Board and the wider team at BenevolentAI, I would like to thank Ken and Mike for the transformational contributions they have made to the Company and we are grateful for the positive legacy they leave behind.”

END


 

About BenevolentAI

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track record of scientifically validated discoveries. The BenevolentAI Platform™ powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York. 

Contacts for BenevolentAI:     

Media:
Rajin Kang - VP Communications

rajin.kang@benevolent.ai

Investors:

Fleur Wood – Investor Relations 

fleur.wood@benevolent.ai
investors@benevolent.ai

Forward-Looking Statements

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "plans", "targets", "aims", "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "should" and similar expressions. Forward-looking statements include statements regarding objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; economic outlook and industry trends; developments in BenevolentAI’s markets; the impact of regulatory initiatives; and/or the strength of BenevolentAI’s competitors. These forward-looking statements reflect, at the time made, BenevolentAI’s beliefs, intentions and current targets/aims. Forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. The forward-looking statements in this release are based upon various assumptions based on, without limitation, management's examination of historical operating trends, data contained in BenevolentAI’s records, and third-party data. Although BenevolentAI believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond BenevolentAI’s control. Forward-looking statements are not guarantees of future performance and such risks, uncertainties, contingencies and other important factors could cause the actual outcomes and the results of operations, financial condition and liquidity of BenevolentAI or the industry to differ materially from those results expressed or implied by such forward-looking statements. The forward-looking statements speak only as of the date of this release. No representation or warranty is made that any of these forward-looking statements or forecasts will come to pass or that any forecast result will be achieved.

More Posts

You Might Also Like

News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022
News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022